https://ntp.niehs.nih.gov/go/5612

TDMS Study 89029-12 Pathology Tables

NTP Experiment-Test: 89029-12         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03
Study Type: SUBCHRON 90-DAY                    MAGNETIC FIELDS + DMBA INITIATION PROMOTION                        Date: 01/30/98
Route: MAGNETIC FIELDS                                                                                            Time: 16:02:02
                    20MG(5MGX4)DMBA V 50 HZ/1G 20MG(5MGX4)DMBA V 50 HZ/5G 20MG(5MGX4)DMBA V 60 HZ/1G 20MG(5MGX4)DMBA 
       Facility:  Battelle Northwest
       Chemical CAS #:  EMF + DMBA
       Lock Date:  10/14/97
       Cage Range:  All
       Reasons For Removal:    All
       Removal Date Range:     All
       Treatment Groups:       Include 001    20 DMBA CONTROL
                               Include 003    50 HZ/1G 20 DMBA
                               Include 005    50 HZ/5G 20 DMBA
                               Include 004    60 HZ/1G 20 DMBA
a  Number of animals examined microscopically at site and number of animals with lesion
                                                              Page   1
NTP Experiment-Test: 89029-12         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03
Study Type: SUBCHRON 90-DAY                    MAGNETIC FIELDS + DMBA INITIATION PROMOTION                        Date: 01/30/98  
Route: MAGNETIC FIELDS                                                                                            Time: 16:02:02  
____________________________________________________________________________________________________________________________________
         SPRAGUE-DAWLEY RATS FEMALE                20 DMBA      50 HZ/1G     50 HZ/5G     60 HZ/1G                                  
                                                   CONTROL      20 DMBA      20 DMBA      20 DMBA                                  
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY                                                                                                                 
  Animals Initially In Study                         100          100          100          100                                     
  Early Deaths                                                                                                                      
    Natural Death                                      3            6            4            2                                      
    Moribund Sacrifice                                 3            7            4            3                                  
  Survivors                                                                                                                         
    Terminal Sacrifice                                93           86           92           94                                     
    Natural Death                                                   1                         1                                    
    Moribund Sacrifice                                 1                                                                            
  Animals Examined Microscopically                   100          100          100          100                                     
____________________________________________________________________________________________________________________________________
 ALIMENTARY SYSTEM                                                                                                                  
   Liver                                              (100)        (100)        (100)        (100)                                  
      Angiectasis                                                                1 (1%)                                            
      Clear Cell Focus                                 1 (1%)                    3 (3%)       3 (3%)                                
      Fatty Change                                                  2 (2%)       1 (1%)       2 (2%)                                
      Hematopoietic Cell Proliferation                19 (19%)     12 (12%)     12 (12%)     22 (22%)                               
      Hepatodiaphragmatic Nodule                       1 (1%)                                                                       
      Necrosis                                                      1 (1%)       1 (1%)       2 (2%)                                
      Centrilobular, Necrosis                          1 (1%)       3 (3%)       1 (1%)       1 (1%)                                
____________________________________________________________________________________________________________________________________
 CARDIOVASCULAR SYSTEM                                                                                                              
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
 ENDOCRINE SYSTEM                                                                                                                   
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
 GENERAL BODY SYSTEM                                                                                                                
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
 GENITAL SYSTEM                                                                                                                     
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                             Page    2                                                              
NTP Experiment-Test: 89029-12         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03
Study Type: SUBCHRON 90-DAY                    MAGNETIC FIELDS + DMBA INITIATION PROMOTION                        Date: 01/30/98  
Route: MAGNETIC FIELDS                                                                                            Time: 16:02:02  
____________________________________________________________________________________________________________________________________
         SPRAGUE-DAWLEY RATS FEMALE                20 DMBA      50 HZ/1G     50 HZ/5G     60 HZ/1G                                  
                                                   CONTROL      20 DMBA      20 DMBA      20 DMBA                                  
____________________________________________________________________________________________________________________________________
 HEMATOPOIETIC SYSTEM                                                                                                               
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
 INTEGUMENTARY SYSTEM                                                                                                               
   Mammary Gland                                      (100)        (100)        (100)        (100)                                  
      Dilatation                                                                 1 (1%)                                
      Hyperplasia                                      4 (4%)                    3 (3%)       7 (7%)                                
      Inflammation, Chronic                                                      1 (1%)       2 (2%)                                
____________________________________________________________________________________________________________________________________
 MUSCULOSKELETAL SYSTEM                                                                                                             
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
 NERVOUS SYSTEM                                                                                                                     
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
 RESPIRATORY SYSTEM                                                                                                                 
   Lung                                               (100)        (100)        (100)        (100)                                  
      Foreign Body                                                               1 (1%)                                
      Inflammation, Chronic                            1 (1%)                    1 (1%)                                
      Thrombosis                                                                              1 (1%)
      Alveolar Epithelium, Hyperplasia                 6 (6%)                    5 (5%)       4 (4%)                                
      Alveolus, Infiltration Cellular, Histiocyte     11 (11%)      2 (2%)      15 (15%)      6 (6%)                               
   Trachea                                            (1)                                                                           
      Metaplasia, Squamous                             1 (100%)                                                                     
      Mineralization                                   1 (100%)                                                                     
____________________________________________________________________________________________________________________________________
 SPECIAL SENSES SYSTEM                                                                                                              
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
 URINARY SYSTEM                                                                                                                     
   Kidney                                             (100)        (100)        (100)        (100)                                  
      Hydronephrosis                                                1 (1%)                    1 (1%)                                             
      Infarct                                                       1 (1%)                                                          
      Inflammation, Chronic Active                                               1 (1%)                                
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                             Page    3                                                              
NTP Experiment-Test: 89029-12         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03
Study Type: SUBCHRON 90-DAY                    MAGNETIC FIELDS + DMBA INITIATION PROMOTION                        Date: 01/30/98  
Route: MAGNETIC FIELDS                                                                                            Time: 16:02:02  
____________________________________________________________________________________________________________________________________
         SPRAGUE-DAWLEY RATS FEMALE                20 DMBA      50 HZ/1G     50 HZ/5G     60 HZ/1G                                  
                                                   CONTROL      20 DMBA      20 DMBA      20 DMBA                                  
____________________________________________________________________________________________________________________________________
URINARY SYSTEM - CONT                                                                                                               
      Mineralization                                   2 (2%)                    1 (1%)       2 (2%)                                
      Nephropathy                                     15 (15%)     16 (16%)     10 (10%)     16 (16%)                               
      Pelvis, Inflammation, Suppurative                                          1 (1%)                                
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                             Page    4                                                              
                             ------------------------------------------------------------                                           
                             ----------              END OF REPORT             ----------                                           
                             ------------------------------------------------------------